SCA
GILD icon

Stuart Chaussee & Associates’s Gilead Sciences GILD Stock Holding History

Stuart Chaussee & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-230
Closed -$15K – 187
2021
Q1 		$15K Hold
230
– – 0.01% 102
2020
Q4 		$13K Hold
230
– – 0.01% 64
2020
Q3 		$15K Hold
230
– – 0.01% 64
2020
Q2 		$18K Buy
+230
New +$17.6K 0.01% 46

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Stuart Chaussee & Associates's GILD Position: Q2 2021 in Review

Stuart Chaussee & Associates sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 230 shares — an estimated $15K sold.

Stuart Chaussee & Associates first reported a position in GILD in Q2 2020 and held it in 4 quarters. The position peaked at $18K in Q2 2020. 1,544 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

  • Stuart Chaussee & Associates reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 230 Gilead Sciences shares in Q2 2021, an estimated $15K.
  • Stuart Chaussee & Associates first reported a position in Gilead Sciences in Q2 2020 and held it in 4 quarters.
  • Stuart Chaussee & Associates's Gilead Sciences position peaked at $18K in Q2 2020.
  • 1,544 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.